The Future of Cardiac Imaging in the Diagnosis, 2nd Edition

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 1023

Special Issue Editor

Special Issue Information

Dear Colleagues,

Over the years, significant progress has been made in cardiovascular imaging techniques, leading to improved diagnosis and treatment of cardiovascular diseases. The 2nd edition of this Special Issue, titled “The Future of Cardiac Imaging in the Diagnosis”, aims to explore innovative imaging modalities that are being used to assess cardiac structure and function, such as echocardiography, cardiac magnetic resonance imaging (MRI), computed tomography (CT), and nuclear imaging.

We welcome papers that present the latest research findings and clinical applications of these imaging techniques. This Special Issue explores the role of cardiovascular imaging in the early detection of cardiovascular diseases, risk stratification, and treatment evaluation; addresses the challenges and limitations faced by cardiovascular imaging; and proposes potential solutions. Moreover, it discusses the future prospects of cardiovascular imaging, including emerging technologies and novel imaging techniques. These advancements have the potential to revolutionize cardiovascular care by providing more accurate and detailed information about the heart and blood vessels.

Overall, this Special Issue aims to provide readers with an overview of the current progress in cardiovascular imaging, highlighting its significance in the diagnosis, management, and prevention of cardiovascular diseases, while also exploring the potential of future developments in this rapidly evolving field.

Prof. Dr. Grigorios Korosoglou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular imaging
  • diagnosis and management
  • early detection
  • risk stratification
  • emerging technologies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

18 pages, 2073 KB  
Article
Longitudinal Effects of Lipid-Lowering Treatment on High-Risk Plaque Features and Pericoronary Adipose Tissue Attenuation Using Serial Coronary Computed Tomography
by Loris Weichsel, Florian André, Matthias Renker, Lukas D. Weberling, Philipp Breitbart, Daniel Overhoff, Meinrad Beer, Borbála Vattay, Sebastian Buss, Mohamed Marwan, Stefan Baumann, Andreas A. Giannopoulos, Natalia Solowjowa, Sebastian Kelle, Norbert Frey, Grigorios Korosoglou and on behalf of the LOCATE Investigators
Diagnostics 2025, 15(18), 2340; https://doi.org/10.3390/diagnostics15182340 - 16 Sep 2025
Viewed by 678
Abstract
Aim: To evaluate the impact of different lipid-lowering treatment intensities on high-risk plaque features and pericoronary adipose tissue (PCAT) attenuation in patients undergoing serial coronary computed tomography angiography (CCTA). Methods: Individuals with suspected or known coronary artery disease (CAD) from 11 [...] Read more.
Aim: To evaluate the impact of different lipid-lowering treatment intensities on high-risk plaque features and pericoronary adipose tissue (PCAT) attenuation in patients undergoing serial coronary computed tomography angiography (CCTA). Methods: Individuals with suspected or known coronary artery disease (CAD) from 11 imaging centers who underwent serial CCTA examinations were retrospectively analyzed. Plaque volumes and PCAT were quantified, and the presence of high-risk plaque features was semi-quantitatively assessed using the plaque feature score (PFS). Results: In total, 216 consecutive patients (mean age 63.1 ± 9.7 years, 26.4% female) were included. The mean observation and treatment timespan between the CCTA scans was 824.5 (interquartile range (IQR) = 463.0–1323.0) days (27.5 months). The regression of high-risk features was more common with high-intensity versus low or no lipid-lowering treatment (HR = 4.6, 95%CI = 1.8–12.0, p < 0.001) and was associated with the attenuated increase in non-calcified plaque volume (p < 0.001). PCATmean decreased with increasing intensity of lipid-lowering treatment (p = 0.01) but no associations were observed between the changes in PCAT and PFS or plaque volumes. Lipid-lowering drug intensity was predictive of PFS regression (p < 0.001), whereas baseline PCATRCA was predictive for PFS progression (p = 0.03), both independent of age, cardiovascular risk factors, and baseline plaque volumes. Conclusions: PCAT predicts the progression of high-risk coronary plaque features. High-intensity lipid-lowering drugs may cause the regression of high-risk plaque features through a plaque ‘delipidization’ process. Future trials are now warranted, studying if this process is potentially associated with improved clinical outcomes. Full article
(This article belongs to the Special Issue The Future of Cardiac Imaging in the Diagnosis, 2nd Edition)
Show Figures

Figure 1

Other

Jump to: Research

6 pages, 3663 KB  
Interesting Images
A Multi-Modality Approach to the Assessment of a Right Atrium Mass in a Female Patient with Breast Cancer Undergoing Neoadjuvant Chemotherapy
by Małgorzata Chlabicz, Paweł Muszyński, Joanna Kruszyńska, Piotr Kazberuk, Magdalena Róg-Makal, Magdalena Lipowicz, Urszula Matys, Anna Tomaszuk-Kazberuk, Marcin Kożuch and Sławomir Dobrzycki
Diagnostics 2025, 15(21), 2683; https://doi.org/10.3390/diagnostics15212683 - 23 Oct 2025
Viewed by 206
Abstract
Echocardiography remains a vital part of the initial assessment and monitoring of oncological patients. It allows for proper treatment selection but can also reveal life-threatening complications, including impaired left ventricular function or thromboembolism. It can rarely detect intracardiac masses that require further investigation. [...] Read more.
Echocardiography remains a vital part of the initial assessment and monitoring of oncological patients. It allows for proper treatment selection but can also reveal life-threatening complications, including impaired left ventricular function or thromboembolism. It can rarely detect intracardiac masses that require further investigation. In the presented case, a 51-year-old female patient with left-sided breast cancer, who had undergone neoadjuvant chemotherapy, was hospitalised due to a right atrial mass identified via routine transthoracic echocardiography (TTE). Initial anticoagulation therapy showed no clinical improvement. Follow-up TTE revealed a 12 × 19 mm hyperechogenic, mobile mass in the right atrium (RA). Computed tomography angiography (CTA) ruled out pulmonary embolism and revealed that the mass was located close to the tip of the vascular access port. Transoesophageal echocardiography showed that the lesion was not connected to the vascular port. Based on location and mobility, the lesion was most consistent with a cardiac myxoma. After the Heart Team made a decision, endovascular intervention using a vacuum-assisted device was performed without complications. Histopathological examination excluded thrombosis and myxoma, revealing a fibro-inflammatory lesion. A multimodality approach is necessary to assess RA masses. However, even an extensive evaluation could be misleading, so treatment options should always be subject to the Heart Team’s decision. Full article
(This article belongs to the Special Issue The Future of Cardiac Imaging in the Diagnosis, 2nd Edition)
Show Figures

Figure 1

Back to TopTop